SMA, or spinal muscular atrophy, is a genetic disorder that causes progressive muscle weakness by destroying the nerve cells responsible for voluntary movement. It ranges from a severe, life-threatening condition in infants to a mild form of muscle weakness in adults, depending on the type. SMA is caused by a missing or mutated gene called SMN1, which produces a protein essential for the survival of motor neurons in the spinal cord.
Without enough of this protein, motor neurons gradually die off. Because these are the nerve cells that tell your muscles to move, their loss leads to muscles shrinking and weakening over time. The weakness tends to be symmetrical, worse in the legs than the arms, and more pronounced closer to the trunk of the body (shoulders, hips, and thighs) than in the hands and feet.
How SMA Affects the Body
The core problem in SMA is the degeneration of specific motor neurons in the spinal cord. These neurons carry signals from the brain to the muscles. When they die, the muscles they control stop receiving instructions and gradually waste away. This process typically follows a pattern: a sharp decline in motor function soon after symptoms first appear, followed by a long plateau where function remains relatively stable.
SMA does not affect thinking, learning, or sensation. People with SMA have normal intelligence and can feel touch, temperature, and pain just like anyone else. The disability is purely motor, affecting the ability to move, breathe, swallow, or hold posture depending on severity.
The Five Types of SMA
SMA is classified into types based on when symptoms appear and which motor milestones a person can reach. The number of copies someone has of a backup gene called SMN2 plays a major role in determining severity. More copies generally mean a milder form.
Type 0
This is extremely rare and the most severe form. Symptoms begin before birth, and infants are born with profound weakness and serious difficulty breathing and feeding.
Type 1
The most common severe form, Type 1 is usually evident before six months of age. Babies have significant muscle weakness and struggle with breathing, coughing, and swallowing. Without treatment, most children with Type 1 cannot sit independently and historically had very short life expectancies. Difficulty swallowing is nearly universal, and many require feeding tubes along with breathing support such as noninvasive ventilation during sleep or, in some cases, a tracheostomy.
Type 2
Symptoms appear between 6 and 18 months of age. Children with Type 2 can learn to sit without support but are unable to stand or walk independently. Scoliosis (curvature of the spine) is common as they grow, and some degree of respiratory weakness develops over time, though it is less severe than in Type 1.
Type 3
Symptoms show up after 18 months. Children with Type 3 can walk on their own, at least for a period of their lives, but may have trouble running, climbing stairs, or getting up from a chair. Some lose the ability to walk later in life and begin using a wheelchair, at which point scoliosis becomes more likely. People with Type 3 typically have little or no respiratory weakness and a normal life expectancy.
Type 4
The mildest form, Type 4 develops after age 18. It presents as mild weakness in the legs and hips. People with adult-onset SMA retain the ability to walk, have a normal life expectancy, and do not develop the breathing or nutritional problems seen in more severe types. It accounts for a very small proportion of all SMA cases.
Daily Life and Mobility
What SMA looks like day to day depends entirely on the type and how early treatment began. For someone with Type 3 who can still walk, the disability might mean fatigue after short distances, difficulty with stairs, or an unusual gait caused by hip weakness. For someone with Type 2 who uses a power wheelchair, daily life involves adapting tasks for limited arm strength and monitoring respiratory health.
For children with Type 1, the level of support is intensive. Respiratory care often includes a machine that helps clear mucus from the airways (used at least twice daily), nighttime breathing support with a bilevel pressure device, and sometimes full-time ventilation. Feeding tubes are standard because swallowing safely becomes difficult or impossible. These interventions, when started proactively, are associated with longer survival.
Across all types, people with SMA commonly use some combination of mobility aids, from lightweight manual wheelchairs and power chairs to standing frames and braces. Physical and occupational therapy help maintain range of motion and adapt daily tasks.
How SMA Is Diagnosed
SMA is confirmed through genetic testing that looks for a missing or mutated SMN1 gene. This test catches roughly 95% of cases. Increasingly, SMA is being detected before any symptoms appear through newborn screening programs. As of mid-2024, about 64% of newborns in the EU are screened for SMA at birth, and screening is expanding in the U.S. and other countries.
Early detection matters enormously. Clinical trials have shown that infants treated before six weeks of age achieve significantly better motor milestones than those treated later. Pre-symptomatic infants with milder genetic profiles who receive treatment have reached motor milestones similar to healthy infants, something that would have been unthinkable before modern therapies existed. The ideal window for starting treatment is within the first two weeks of life.
Treatments That Have Changed the Outlook
Three disease-modifying therapies have been approved by the FDA, and they have fundamentally altered what SMA means for many families. None of them cure SMA, but they can slow progression, preserve motor function, and in some cases help patients gain abilities they would never have developed otherwise.
The first approach works by helping the backup gene (SMN2) produce more functional protein. One version is given as a spinal injection every four months, and another is taken as a daily oral liquid. The third treatment is a one-time gene therapy delivered through an IV. It introduces a working copy of the SMN1 gene into the body. All three have improved survival rates, reduced the need for ventilators, and enabled patients to hit motor milestones that were previously out of reach.
For children under two with Type 1 SMA, treatment has shown improved survival compared to no treatment. The results are most dramatic when therapy begins before symptoms appear, which is why newborn screening has become such a priority. Treatment is now being offered across all types and ages, though the greatest benefit comes with the earliest intervention.
Newer therapies are also being studied that target the muscles directly rather than the underlying gene problem. One drug currently in clinical trials works by blocking a natural process that limits muscle growth. In a trial of 188 patients aged 2 to 21 with Type 2 or Type 3 SMA, children aged 2 to 12 who received the drug showed statistically significant improvements in motor function scores compared to placebo. These muscle-directed treatments are being developed as potential add-on therapies alongside existing gene-based treatments.
Long-Term Outlook by Type
The prognosis for SMA has shifted dramatically in the past decade. For Type 1, the natural course without treatment historically meant death or permanent ventilation within the first two years. With modern therapies started early, many of these children are surviving longer and gaining motor skills. However, outcomes still vary, and children who begin treatment after significant motor neuron loss has already occurred may see less benefit.
Types 2 and 3 carry a more favorable long-term outlook. Type 3 patients typically have a normal lifespan, and many remain ambulatory well into adulthood, especially with ongoing physical therapy and, increasingly, disease-modifying treatment. Type 2 patients face more variability but generally live into adulthood, with respiratory health being the most important factor to manage over time.
Type 4 has the least impact on life expectancy and daily function. Many adults with Type 4 SMA are diagnosed after years of mild symptoms and may not require significant intervention beyond physical therapy and monitoring.
Because treatments are so new, the long-term trajectory for children diagnosed through newborn screening and treated pre-symptomatically is still being mapped. What’s clear is that these children are developing in ways that don’t fit the old classification system at all, creating entirely new patterns of the disease that doctors are still learning to describe.